Screener
Sionna Therapeutics SION Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income | 2,820 | 3,177 |
| Net loss | $(26,779) | $(16,482) |
| Net loss per share, basic and diluted | $(0.60) | $(0.62) |
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 |
| Comprehensive loss: | ||
| Net loss | $(26,779) | $(16,482) |
| Unrealized loss on marketable securities | (624) | (67) |
| Total other comprehensive loss | (624) | (67) |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's shares (diluted)?
- Sionna Therapeutics (SION) reported shares (diluted) of 44.9M in Q1 2026.
- How has Sionna Therapeutics's shares (diluted) changed year-over-year?
- Sionna Therapeutics's shares (diluted) increased by 68.9% year-over-year, from 26.6M to 44.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Sionna Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude